The effect of citalopram on gene expression profile of Alzheimer lymphocytes

Neurochemical Research

Volumn 29, Issue 8, 2004, Pages 1563-1570

  Palots, Andrs ^a,b   Pusks, Lszl G ^b   Kitajka, Klra ^a   Palots, Mikls ^a   Molnr, Jzsef ^a   Pkski, Magdolna ^a   Janka, Zoltn ^a   Penke, Botond ^b   Klmn, Jnos ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b INSTITUTE OF EXPERIMENTAL MEDICINE   (Hungary)

Author keywords

Alzheimers disease; antidepressant; citalopram; gene expression; lymphocyte; microarray

Indexed keywords

CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADRENERGIC ACTIVITY; AGED; ALZHEIMER DISEASE; ARTICLE; CELL ADHESION; CELL PROTECTION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DNA MICROARRAY; DRUG EFFECT; FEMALE; GENE EXPRESSION; GENE FUNCTION; GENE SEQUENCE; HUMAN; HUMAN CELL; ION CURRENT; LYMPHOCYTE; MALE; MOLECULAR MECHANICS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL;

EUKARYOTA;

EID: 3042826947     PISSN: 03643190     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:NERE.0000029570.57903.74     Document Type: Article

References (53)

1. Selkoe, D. J. The molecular pathology of Alzheimer's disease. 1991. Neuron 6:487-498.
2. Terry, R. D. Neuropathological changes in Alzheimer disease. 1994. Prog. Brain Res. 101:383-390.
3. Lyketsos, C. G., Steinberg, M., Tschantz, J., Norton, M., Steffens, D., and Breitner, J. C. S. 2000. Mental and behavioral disturbances in dementia: Findings from the Cache County Study on Memory in Aging. Am. J. Psychiatry 157:708-714.
4. Olin, J. T., Schneider, L. S., Katz, I. R., Meyers, B. S., Alexopoulos, G. S., Breitner, J. C., Bruce, M. L., Caine, E. D., Cummings, J. L., Devanand, D. P., Krishnan, K. R., Lyketsos, C. G., Lyness, J. M., Rabins, P. V., Reynolds, C. F. 3rd, Rovner, B. W., Steffens, D. C., Tariot, P. N., and Lebowitz, B. D. 2002. Provisional diagnostic criteria for depression of Alzheimer disease. Am. J. Geriatr. Psychiatry 10:125-128.
5. Duman, R. S., Heninger, G. R., and Nestler, E. I. 1997. A molecular and cellular theory of depression. Arch. Gen. Psychiatry 54:597-606.
6. Berger, B. Neurotransmitter anomalies in Alzheimer's disease. 1984. Rev. Neurol. 10:539-552.
7. Bowen, D. M., Allen, S. J., Benton, J. S., Goodhardt, M. J., Haan, E. A., Palmer, A. M., Sims, N. R., Smith, C. C., Spillane, J. A., Esiri, M. M., Neary, D., Snowdo, J. S., Wilcock, G. K., Davison, A. N. 1983. Biochemical assessment of serotonergic and cholinergic dysfunction and cerebral atrophy in Alzheimer's disease. J. Neurochem. 41:266-272.
8. Palotás, M., Palotás, A., Puskás, L. G., Kitajka, K., Pákáski, M., Janka, Z., Molnár, J., Penke, B., and Kálmán, J. 2004. Gene expression profile analysis of the rat cortex following treatment with imipramine and citalopram. Int. J. Neuropsychopharm. (in press).
9. i-level of fibroblasts from Alzheimer patients and control individuals. Neurochem. Res. 26:817-820.
10. Zubenko, G. S., Cohen, B. M., Growdon, J., and Corkin, S. 1984. Cell membrane abnormality in Alzheimer's disease. Lancet 2:235.
11. Kálmán, J., Dey, I., Ilona, S. V., Matkovics, B., Brown, D., Janka, Z., Farkas, T., and Joó, F. 1994. Platelet membrane fluidity and plasma malondialdehyde levels in Alzheimer's demented patients with and without family history of dementia. Biol. Psychiat. 35:190-194.
12. Zubenko, G. S. 1989. Endoplasmic reticulum abnormality in Alzheimer's disease: selective alteration in platelet NADH-cytochrome C reductase activity. J. Geriatr. Psychiat. Neurol. 2:3-10.
13. Di Luca, M., Pastorino, L., Bianchetti, A., Perez, J., Vignolo, L. A., Lenzi, G. L., Trabucchi, M., Cattabeni, F., and Padovani, A. 1988. Differential level of platelet amyloid beta precursor protein isoforms: an early markers for Alzheimer's disease. Arch. Neurol. 55:1195-1200.
14. Perry, R. H., Wilson, I. D., Bober, M. J., Atack, J., Blessed, G., Tomlinson, B. E., and Perry, E. K. 1982. Plasma and erythrocyte acetylcholinesterase in senile dementia of Alzheimer type. Lancet 1:174-175.
15. Palotás, A., Kálmán, J., Palotás, M., Juhász, A., Janka, Z., and Penke, B. 2002. β-amyloid induced increase in the resting intracellular calcium concentration gives support to tell Alzheimer lymphocytes from control ones. Brain Res. Bull. 58:203-205.
16. Etcheberrigaray, R. and Bhagavan, S. Ionic and signal transduction alterations in Alzheimer's disease: Relevance of studies on peripheral cells. 1999. Mol. Neurobiol. 20:93-109.
17. Eckert, A., Cotman, C. W., Zerfass, R., Hennerici, M., and Muller, W. E. Lymphocytes as cell model to study apoptosis in Alzheimer's disease: vulnerability to programmed cell death appears to be altered. 1998. J. Neurol. Transm. Suppl. 54:259-267.
18. Bergman, M., Salman, H., Beloosesky, Y., Djaldetti, M., and Bessler, H. 2002. Are peripheral blood cells from patients with Alzheimer's disease more sensitive to apoptotic stimuli? Alzheimer Dis. Assoc. Dis. 16:156-160.
19. Mórocz, M., Kálmán, J., Juhász, A., Sinkó, I., McGlynn, A. P., Downes, C. S., Janka, Z., Raskó, I. 2002. Elevated levels of oxidative DNA damage in lymphocytes from patients with Alzheimer's disease. Neurobiol. Aging 23:47-53.
20. Dolman, C. L. 1984. Diagnosis of neurometabolic disorders by examination of skin biopsies and lymphocytes. Semin. Diagn. Pathol. 1:82-97.
21. Kalman, J., Kitajka, K., Pákáski, M., Zvara, Á., Juhász, A., Vincze, G., Janka, Z., and Puskás, L. G. 2004. Gene expression profile analysis of lymphocytes from Alzheimer's patients. (in press)
22. Kitajka, K., Puskás, L. G., Zvara, Á., Hackler, L. Jr., Barcelo-Coblijn, G., Yeo Y. K., and Farkas T. 2002. The role of n-3 polyunsaturated fatty acids in brain: modulation of rat brain gene expression by dietary n-3 fatty acids. Proc. Natl. Acad. Sci. USA 99:2619-2624.
23. Puskás, L. G., Hackler, L. Jr., Kovács, G., Kupihár, Z., Zvara Á., Micsik, T., and van Hummelen P. 2002. Recovery of cyanine-dye nucleotide triphosphates. Anal. Biochem. 305:279-281.
24. Puskás, L. G., Zvara Á, Hackler, L. J., and van Hummelen, P. 2002. Comparison of different sample amplification method for microarray gene expression analysis. RNA amplification results in reproducible microarray data with slight ratio bias. Biotechniques 32:1330-1340.
25. Herwig, S., and Strauss, M. 1997. The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. Eur. J. Biochem. 246:581-601.
26. Rohn, T. T., Head, E., Su, J. H., Anderson, A. J., Bahr, B. A., Cotman, C. W., and Cribbs, D. H. 2001. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am. J. Pathol. 158:189-198.
27. Takeda, M., Tatebayashi, Y., and Nishimura, T. 1992. Change in the cytoskeletal system in fibroblasts from patients with familial Alzheimer's disease. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 16:317-328.
28. Tollefson, G. D., Godes, M., Warren, J. B., Haus, E., Luxenberg, M., and Garvey, M. 1989. Lymphopenia in primary degenerative dementia. J. Psychiatr. Res. 23:191-199.
29. Serafeim, A. and Gordon, J. 2001. The immune system gets nervous. Curr. Opin. Pharmacol. 1:398-403.
30. Nagga, A. K. and Marcusson, J. 1998. Associated physical disease in a demented population. Aging Milano 10:440-444.
31. McGeer, P. L. and McGeer, E. G. 2002. The possible role of complement activation in Alzheimer's disease. Trends Mol. Med. 8:519-523.
32. Mossner, R. and Lesch, K. P. 1998. Role of serotonin in the immune system and in neuroimmune interactions. Brain Behav. Immun. 12:249-271.
33. Stefulj J., Jernej, B., Cicin-Sain, L., Rinner, I., and Schauenstein, K. mRNA expression of serotonin receptors in cells of the immune tissues of the rat. 2000. Brain Behav. Immun. 14:219-224.
34. Aune, T. M., Kelley, K. A., Ranges, G. E., Bombara, M. P., 1990. Serotonin-activated signal transduction via serotonin receptors on Jurkat cells. J. Immunol. 145:1826-1832.
35. Plaut, M. Lymphocyte hormone receptors. 1987. Ann. Rev. Immunol. 5:621-629.
36. Hellstrand, K. and Hermodsson, S. Role of serotonin in the regulation of human natural killer cell cytotoxicity, 1987. J. Immunol. 139:869-875.
37. Bonnet, M., Lespinats, G., and Burtin, C. Histamine and serotonin suppression of lymphocyte response to phytohemagglutinin and allogenic cells. 1984. Cell. Immunol. 83:280-291.
38. Bellinger, D. L., Felten, S. Y., and Felten, D. L. 1988. Maintenance of non-adrenergic sympathetic innervation in the involuted thymus of the aged Fisher 344 rat. Brain Behav. Immunol. 2:133-150.
39. Hershey, J. W. B. and Merrick, W. C. 2000. Pathway and mechanism of initiation of protein synthesis. Pages 33-88, in Sonenberg N., Hershey, J. W. B., Mathews, M. B., eds. Translational control of gene expression, (2nd Ed.), Cold Spring Harbor: Cold Spring Harbor Laboratory Press.
40. Schauenstein, K., Felsner, P., Rinner, I., Liebmann, P. M., Stevenson, J. R., Westermann, J., Haas, H. S., Cohen, R. L., and Chambers, D. A. 2000. In vivo immunomodulation by peripheral adrenergic and cholinergic agonists/antagonists in rat and mouse models. Ann. N. Y. Acad. Sci. 917:618-627.
41. Rabey, J. M., Shenkman, L., Gilad, G. M. 1986. Cholinergic muscarinic binding by human lymphocytes: change with aging, antagonist treatment, and senile dementia of the Alzheimer type. Ann. Neurol. 20:628-631.
42. 2-like receptors on human peripheral blood lymphocytes: a radioligand binding assay and immunocytochemical study. J. Auton. Pharmacol. 19:151-159.
43. 3 dopamine receptor gene and a novel variant transcript generated by alternative splicing in human peripheral blood lymphocytes. Biochem. Biophys. Res. Commun. 194:374-386.
44. 4 receptor in human peripheral blood lymphocytes: a radioligand binding assay study. Neurosci. Lett. 229:130-134.
45. Takahashi, N., Nagai, Y., Ueno, S., Saeki, Y., and Yanagihara, T. 1992. Human peripheral blood lymphocytes express D5 dopamine receptor gene and transcribe the two pseudogenes. FEBS Lett. 314:23-25.
46. Rocca, P., Ferrero, P., Gualerzi, A., Zanalda, E., Maina, G., Bergamasco, B., and Ravizza, L. 1991. Peripheral type of benzodiazepine receptors in anxiety disorders. Acta Psychiatr. Scand. 84:537-544.
47. Stanisz, A. N., Scicchitano, R., Dazin, P., Bienenstock, J., and Payan, D. G. 1987. Distribution of substance P receptors on murine spleen and Peyer's patch T and B cells. J. Immunol. 139:749-756.
48. Evans, C. J., Erdélyi, E., Barchas, J. D. 1986. Candidate opioid peptides for the interaction with the immune system. Pages 3-16, in Plotnikoff, N. P., Faith, R. E., Murgo, A. J. and Goog, A., (eds.), Enkephalins and endorphins, Plenum, New York.
49. Viik, P., Opstad, P. K., and Boyum A. Binding of vasoactive intestinal polypeptide (VIP) by human monocytes: demonstration of specific binding sites. 1985. Regul. Pept. 12:145-153.
50. Bishopric, N. H., Cohen, H. J., and Lefkowitz, R. J. β-adrenergic receptors in lymphocyte subpopulations. 1980. J. Allergy Clin. Immunol. 63:29-33.
51. Shenkman, L., Rabey, J. M., Gilad, G. M. Cholinergic muscarinic binding by rat lymphocytes: effects of antagonist treatment, strain and aging. 1991. Brain Res. 564:203-219.
52. D'Amato, R. J., Zweig, R. M., Whitehouse, P. J., Wenk, G. L., Singer, H. S., Mayeux, R., Price, D. L., and Snyder, S. H. 1987. Aminergic systems in Alzheimer's disease and Parkinson's disease. Ann. Neurol. 22:229-236.
53. Zweig, R. M., Ross, C. A., Hedreen, J. C., Steele, C., Cardillo, J. E., Whitehouse, P. J., Folstein, M. F., Price, D. L. 1988. The neuropathology of aminergic nuclei in Alzheimer's disease. Ann. Neurol. 24:233-242.